Second Autologous Stem Cell Transplantation as Salvage Therapy for Multiple Myeloma: Impact on Progression-Free and Overall Survival

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 5, 2012, Pages 773-779

  Jimenez Zepeda, Victor H ^a   Mikhael, Joseph ^b   Winter, Andrew ^a   Franke, Norman ^a   Masih Khan, Esther ^a   Trudel, Suzanne ^a   Chen, Christine ^a   Kukreti, Vishal ^a   Reece, Donna E ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b MAYO CLINIC   (United States)

Author keywords

Autologous stem cell transplant (ASCT); Multiple myeloma (MM); Overall survival (OS); Progression free survival (PFS); Salvage therapy

Indexed keywords

BORTEZOMIB; BUSULFAN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; LENALIDOMIDE; MELPHALAN; PREDNISONE; THALIDOMIDE; VINCRISTINE;

ADULT; AGED; ARTICLE; ASPIRATION PNEUMONIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; DIARRHEA; DRUG DOSE REDUCTION; DRUG MEGADOSE; ENTEROCOLITIS; FEBRILE NEUTROPENIA; FEMALE; HERPES ZOSTER; HUMAN; LOBAR PNEUMONIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SALVAGE THERAPY; STAPHYLOCOCCAL BACTEREMIA; TREATMENT RESPONSE; WHOLE BODY RADIATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 84859851602     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.10.044     Document Type: Article

References (28)

1. Bjorkstrand B., Gahrton G. High-dose treatment with autologous stem cell transplantation in multiple myeloma: past, present, and future. Semin Hematol 2007, 44:227-233.
2. Harousseau J.L. Role of stem cell transplantation. Hematol Oncol Clin North Am 2007, 21:1157-1174.
3. Kumar L., Ghosh J., Ganessan P., Gupta A., Hariprasad R., Kochupillai V. High-dose chemotherapy with autologous stem cell transplantation for multiple myeloma: what predicts the outcome? Experience from a developing country. Bone Marrow Transplant 2009, 43:481-489.
4. 2) supported by autologous stem cell transplantation is safe and effective in elderly (>or = 65 years) myeloma patients: comparison with younger patients treated on the same protocol. Bone Marrow Transplant 2006, 37:917-922.
5. Engelhardt M., Kleber M., Udi J., et al. Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches. Leuk Lymphoma 2010, 51:1424-1443.
6. Rajkumar S.V. Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol 2011, 86:57-65.
7. Reece D.E. Recent trends in the management of newly diagnosed multiple myeloma. Curr Opin Hematol 2009, 16:306-312.
8. Alvares C.L., Davies F.E., Horton C., Patel G., Powles R., Morgan G.J. The role of second autografts in the management of myeloma at first relapse. Haematologica 2006, 91:141-142.
9. Mehta J., Tricot G., Jagannath S., et al. Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft?. Bone Marrow Transplant 1998, 21:887-892.
10. Mikhael J.R., Zadeh S., Samiee S. Second autologous stem cell transplant (ASCT) as salvage therapy in patients with relapsed multiple myeloma: improve outcomes in patients with longer disease free interval after first ASCT. Blood 2007, 110.
11. Tricot G., Jagannath S., Vesole D.H., Crowley J., Barlogie B. Relapse of multiple myeloma after autologous transplantation: survival after salvage therapy. Bone Marrow Transplant 1995, 16:7-11.
12. Olin R.L., Vogl D.T., Porter D.L., et al. Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma. Bone Marrow Transplant 2009, 43:417-422.
13. Qazilbash M.H., Sallba R., De Lima M., et al. Second autologous stem cell transplant or allogeneic transplantation after failure of first autograft in patients with multiple myeloma. Cancer J 2006, 106.
14. Blade J., Samson D., Reece D., et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998, 102:1115-1123.
15. Durie B.G., Harousseau J.L., Miguel J.S., et al. International uniform response criteria for multiple myeloma. Leukemia 2006, 20:1467-1473.
16. Burzynski J.A., Toro J.J., Patel R.C., et al. Toxicity of a second autologous peripheral blood stem cell transplant in patients with relapsed or recurrent multiple myeloma. Leuk Lymphoma 2009, 50:1442-1447.
17. Hong J.Y., Choi M.K., Kim D.H. Feasibility of second hematopoietic stem cell transplantation using reduced-intensityconditioning with fludarabine and melphalan after a failed autologous hematopoietic stem cell transplantation. Transplant Proc 2010 Nov, 42(9):3723-3728.
18. Krejci M., Adam Z., Buchler T., et al. Salvage treatment with upfront melphalan 100 mg/m(2) and consolidation with novel drugs for fulminant progression of multiple myeloma. Ann Hematol 2010, 89(5):483-487.
19. Bensinger W. Stem-cell transplantation for multiple myeloma in the era of novel drugs. J Clin Oncol 2008, 26:480-492.
20. Kyle R.A., Rajkumar S.V. Treatment of multiple myeloma: a comprehensive review. Clin Lymphoma Myeloma 2009, 9:278-288.
21. Rajkumar S.V., Palumbo A. Management of newly diagnosed myeloma. Hematol Oncol Clin North Am 2007, 21:1141-1156. ix-x.
22. Palumbo A., Rajkumar S.V. Multiple myeloma: chemotherapy or transplantation in the era of new drugs. Eur J Haematol 2010 May, 84(5):379-390.
23. Reece D., Gill W., Masih-Khan E., et al. Efficacy of lenalidomide therapy in patients with relapsed/refractory multiple myeloma: influence of number and timing of prior ASCT(s). Haematologica 2011, (Suppl 1).
24. Harousseau J.L. Integrating novel therapies in the transplant paradigm. Cancer J 2009, 15:479-484.
25. Soledad Molnar V.J.J.Z., Van Wier S., Braggio E., et al. Loss of p53 is a marker of progression in plasma cell neoplasias and is a negative prognostic factor in relapsed disease. Blood 2008, 112:1663.
26. Barlogie B., Hall R., Zander A., Dickie K., Alexania R. High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood 1986, 67:1298-1301.
27. Cook G., Liakopoulou E., Pearce R., et al. Factors influencing the outcome of a second autologous stem cell transplant (ASCT) in relapsed multiple myeloma: a study from the British Society of Blood and Marrow Transplantation Registry. Biol Blood Marrow Transplant 2011, 17:1638-1645.
28. Fenk R., Liese V., Neubauer F., et al. Predictive factors for successful salvage high-dosetherapy in patients with multiple myeloma relapsing after autologous blood stem cell transplantation. Leuk Lymphoma 2011 Aug, 52(8):1455-1462.